Top Stories
-
Columbia research seven years in the making highlights potential therapeutic target for neurodegenerative disease
-
"Hispanics and individuals of African ancestry have been significantly underrepresented in research of Alzheimer’s disease, although engaging underserved minorities is critical..." says Dr. Reitz
Topic
-
Research from Scott Small's lab at Columbia University suggests a different approach to tackling the disease, and a new startup company is now trying to turn that approach into treatments.
-
For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol, or obesity have a higher likelihood of developing Alzheimer’s disease.
Topic
Latest News
- May 22, 2022
Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease.
- April 28, 2022
A recent look inside a baby zebrafish's transparent brain offers clues to how we remember and how we forget.
- April 18, 2022
Studies linked to Cassava Sciences, once a stock market favorite, have been retracted or challenged by medical journals.
- December 11, 2021
Various programs around the country connect neurologic patients and caregivers with the arts. One such example is Arts & Minds, an organization founded by Dr. James M. Noble
Topic
- October 26, 2021
While it may be incurable, there are several ways to treat the symptoms—and one promising but controversial new drug.
Topic
- October 25, 2021
Vagelos College of Physicians and Surgeons and College of Dental Medicine scientists awarded $3.97 million to study link between Alzheimer’s and periodontitis
- October 18, 2021
Dr. Manly was elected to NAM for her pioneering work improving detection of cognitive impairment among racially, culturally, and socio-economically diverse adults
- August 30, 2021
Finding out exactly which type of dementia you or your loved one has may be scary, but it’s important to identify the condition as early as possible
Topic
- July 8, 2021
There is a robust market for books that praise our seemingly feeble habits of mind.
- June 28, 2021
The federal health insurance program may limit who can get the drug, which Biogen priced at $56,000 a year, to limit the financial impact
